APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192 Meeting Abstract
| Authors: | Reiss, K. A.; Hong, S. C.; Kasi, A.; O'Reilly, E. M.; Maithel, S. K.; Yao, X.; Hamilton, S. R.; Boursi, B.; Pishvaian, M. J.; Klempner, S. J.; Domchek, S. M.; Catalano, P. J.; Chiorean, E. G.; Philip, P. A.; O'Dwyer, P. J. |
| Abstract Title: | APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192 |
| Meeting Title: | 2023 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2023 Jan 19-21 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.4_suppl.TPS763 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS763 -- Accession Number: 161485344 -- Entry Date: In Process -- Revision Date: 20230127 -- Publication Type: Article -- Supplement Title: 2/1/2023 Supplement 1 -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
